Unibest

Pharmaceutical intermediates

Lenacapavir sodium Intermediates

4 pharmaceutical intermediates for Lenacapavir sodium. Indication: HIV.

提交项目All intermediates

About Lenacapavir sodium

Originator
Gilead Inc
Indication
HIV
Approved Date
12/22/2022
NCE Patent
12/22/2027
DS/DP
02/28/2034

Available intermediates

4 intermediates currently listed for Lenacapavir sodium. Request specifications, documentation or a quotation for any item below.

Lenacapavir sodium intermediates
Product NameCAS No.Molecular FormulaPhysical Properties
2-((3bS,4aR)-5,5-difluoro-3-(trifluoromethyl)-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)acetic acid1620056-83-8//
4-Chloro-7-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1-(2,2,2-trifluoroethyl)-1H-indazol-3-amine2189684-53-3//
3-Methyl-3-(methylsulfonyl)but-1-yne2109226-54-0//
Carbamic acid, N-[(1S)-1-(3,6-dibromo-2-pyridinyl)-2-(3,5-difluorophenyl)ethyl]-, 1,1-dimethylethyl ester1620056-47-4//

Other programs under L

(LCZ696)LanifibranorLapatinibLarotrectinibLasmiditanLazertinib MesylateLemborexantLenalidomide

Building toward Lenacapavir sodium?

Tell us the step you need covered and the specification you are filing against. We will confirm supply, documentation and lead time.

提交项目 联系团队

我们能如何帮助您？

获取最新活动与法规动态洞察

直接发送到您的邮箱

在此获取行业洞察与 Unibest 动态

联系我们 →